Purpose: The aim of the study is to investigate the effects of ABCB1, ABCC2, UGT2B7 and HNF4a genetic polymorphisms on plasma oxcarbazepine (OXC) concentrations and therapeutic efficacy in Han Chinese patients with epilepsy. Methods: We recruited 116 Han Chinese patients with epilepsy who were receiving OXC monotherapy. Blood samples were taken and OXC levels were measured. The polymorphisms of ABCB1 rs1045642, ABCC2 rs2273697, UGT2B7 rs7439366, and HNF4a rs2071197 were determined. The therapeutic efficacy of OXC at the 1-year time-point was assessed. Data analysis was performed using IBM SPSS Statistics 22.0. Results: The genetic polymorphism of ABCB1 rs1045642 was found to be associated with normalized OXC concentration and therapeutic efficacy in patients with epilepsy (P < 0.05). As for UGT2B7 rs7439366, the allele polymorphism exhibited a correlation with treatment outcome, but not OXC concentration. The polymorphisms of ABCC2 rs2273697 and HNF4a rs2071197 was not associated with OXC concentrations and therapeutic efficacy. Conclusion: These results suggested that ABCB1 rs1045642 and UGT2B7 rs7439366 may affect OXC pharmacokinetics and therapeutic efficacy in Han Chinese patients with epilepsy. However, further studies in larger populations and other ethnic groups are required.
Introduction
Oxcarbazepine (OXC), which is one of the new-generation antiepileptic drugs (AEDs), has been used mainly to treat partial seizures in monotherapy or adjunctive therapy [1] . Wide variability of daily maintenance doses and plasma concentrations has been observed among patients with epilepsy prescribed with OXC. Genetic predisposition may be an important factor contributing to the variability in OXC pharmacokinetics among patients with epilepsy.
P-glycoprotein (P-gp) and multidrug resistance-associated protein (MRP) are important for the transport of AEDs across the blood-brain barrier [2] . P-gp is encoded by the Multidrug resistance 1 (MDR1) gene (also known as ABCB1 gene); MRP is encoded by the ABCC genes. Both proteins and mRNAs are overexpressed in the brain of patients with drug-resistant epilepsy [3] [4] [5] . Researches have found that ABCB1 and ABCC2 genetic polymorphisms were connected with the high incidence of drugresistant epilepsy, probably as the polymorphisms may affect the efflux activity of transporters in the endothelial cells of the bloodbrain barrier, decrease the concentrations of AEDs, and then contribute to the failure of AEDs [6, 7] . Several studies have indicated ABCB1 and ABCC2 polymorphisms may be associated with the carbamazepine (CBZ) concentration and responsiveness [8, 9] . As a 10-keto analog of CBZ, the mechanism of action and efficacy of OXC are comparable to those of CBZ based on structural similarities. Zhang et al has reported P-gp transports OXC and its metabolites [10] , suggesting ABCB1 polymorphisms may exert an effect on OXC pharmacokinetics and treatment outcome. However, a recent study has showed non-significant associations between ABCB1 (rs2032582, rs2032582, rs10234411 and rs1045642) genetic polymorphisms and OXC plasma concentration on monotherapy [11] . To date, related findings were fewer, and the correlation among this commonly studied single nucleotide polymorphisms (SNPs) and OXC responsiveness has not been reported. With regard to ABCC2, Ulfer et al's study has indicated carriers of the ABCC2 rs2273697 variant were more frequent among CBZ/OXC responders in Caucasian patients with childhood epilepsy [12] . However, inconsistent results have been reported in Chinese patients with epilepsy, showing that carriers of the ABCC2 rs2273697 variant alleles required significantly higher OXC maintenance doses to control seizures than noncarriers [13] . Therefore, the association between the SNP and OXC remains unclear.
Once absorbed from the gastrointestinal tract, OXC is reduced immediately to 10,11-dihydro-10-hydroxy-carbazepine (monohydroxy derivative, MHD), which is the main pharmacological active metabolite [14] . The majority of OXC administered is excreted by the kidneys as the inactive glucuronide conjugates of the MHD by weakly inducible microsomal UDP-glucuronosyltransferases (UGTs), OXC, and unchanged MHD [15] . Studies have shown that UGT2B7 rs7439366 and UGT1A9 rs2741049 genetic polymorphisms probably contribute to the variability of enzymatic activity among individuals, resulting in different OXC plasma concentration and treatment response [13, 16] . However, comprehensive studies are required to confirm the findings, and the data regarding the effects on OXC responsiveness was lacking. Hepatocyte nuclear factor 4 alpha (HNF4a) is a liver-enriched master regulator of liver development and differentiation, which directly binds to lots of gene promoters in human and mouse liver [17, 18] . Zhou et al. has reported the polymorphisms in HNF4a rs2071197 was associated with LTG plasma concentration [19] . OXC is oxidized by cytosolic aryl ketone reductase in the liver and thus the potential influence of HNF4a variant (rs2071197) on OXC plasma concentration and efficacy also needs to be explored.
In order to evaluate the associations between these genetic variants and OXC pharmacokinetics and pharmacoresistence, the present study was aiming to identify the effects of candidate SNPs in ABCB1 rs1045642, ABCC2 rs2273697, UGT2B7 rs7439366, and HNF4a rs2071197 on plasma OXC concentrations and therapeutic efficacy in Han Chinese patients with epilepsy receiving OXC monotherapy.
Materials and methods

Subjects
This study consecutively included 116 Han Chinese patients with epilepsy from January 2012 to July 2015. All patients were treated at the Epilepsy Center of the Second Affiliated hospital of Zhejiang University School. Inclusion criterias were as follows: (1) diagnosed as partial seizures by experienced clinicians according to the guidelines for the Classification and Diagnosis of Epilepsy of the International League Against Epilepsy [20] ; (2) prescribed with OXC as monotherapy for >1 month with good compliance; (3) normal renal and hepatic functions; (4) had seizures in the prior 3 months before initiating OXC therapy; (5) no combined medication which was known to affect OXC disposition. Patients were excluded if they had severe organ diseases, mental disorders, or progressive nervous diseases which influenced the evaluation of serum level and treatment outcome of OXC. Besides, patients were excluded if they were prescribed with other AEDs due to adverse effects of OXC within a 1-year follow-up. Informed consents were obtained from all participants, and the study was approved by the Second Affiliated hospital of Zhejiang University School of Medicine Ethics Committee.
OXC quantitation in plasma samples
After a minimum of one month of continuous treatment with OXC monotherapy, peripheral blood samples were drawn from each patient in the early morning before breakfast and OXC administration. Plasma OXC concentrations were measured in the Inspection Department at our hospital, based on reversed phase high-performance liquid chromatography (Beckman System Gold 125 Solvent Module 166 Detector). At the same time, renal and hepatic functions were determined by liver enzymes and creatine, which were both measured by blood test (enzyme coupled assays). Due to obvious differences in oral doses among these patients, normalized plasma concentration of OXC was adjusted by daily dose and body weight.
Therapeutic efficacy analysis
Patients were evaluated at 4 weeks after treatment initiation and then at 3-month intervals thereafter. At each visit, seizure frequency, medication changes and response to AEDs were routinely recorded in clinical notes. By monitoring patients' epileptic seizures over a 1-year follow-up period, the reduction rate in seizure frequency was defined as the difference between the 3-month retrospective baseline frequency and the seizure frequency at the final visit which was reported for the last 3 months prior to the last visit. Good efficacy was defined as seizurefree or a 50% or greater reduction in seizure frequency for at least one year. Poor efficacy was defined as no change or less than 50% reduction in seizure frequency. If patients were prescribed with other AEDs reasonably by experienced epilepsy experts due to the poor control of seizure, they were clpassified into the group of poor efficacy.
Genotyping
Genomic DNA was isolated from the whole blood using the AXYGEN Genomic DNA purification kit. Samples were genotyped for the ABCB1 rs1045642, ABCC2 rs2273697, UGT2B7 rs7439366, and HNF4a rs2071197 by PCR according to the manufacturer's instructions, and primers were designed using Primer Premier 5.0 software (Supplementary Table 1 ). The PCR products were sequenced using the ABI-3730 sequencer (Applied Biosystems, Foster City, CA), and data were expressed with Chromas 3.0, followed by manual adjustment.
Statistical analysis
A Chi square (x2) test was preformed to evaluate the deviation of genotype frequencies with Hardy-Weinberg equilibrium. Fischer's exact test (for comparisons of the categorical data), Student's t-test or analysis of variance (ANOVA) (for comparisons of continuous data), and Mann-Whitney U test or Kruskal-Wallis test (for comparisons of nonparametric continuous data) were used to compare the distributions of demographic characteristics. Group differences of daily dose and normalized OXC concentration were analyzed by Kruskal-Wallis test and Mann-Whitney U test. The Kruskal-Wallis test was to compare three groups of genotypes for each SNP. If any SNP shows different distribution, then the Mann-Whitney U test was applied to see which pair of groups was significantly different. Fisher's exact tests were used to examine if there existed differences in genotype and allele frequencies between good efficacy group and poor efficacy group.
The combined effects of SNPs and non-genetic factors were further assessed by multivariate regression model.
Statistical analysis was performed using SPSS version 22.0 for Windows (SPSS Inc, Chicago, IL, USA). A two-side P value less than 0.05 was considered statistically significant. Table 1 summarizes the clinical and demographic characteristics of all enrolled patients. A total of 116 Han Chinese patients with epilepsy on OXC monotherapy were included (61 male, 55 female). The mean age of the sample was 28 AE 14 years old. The OXC maintenance doses ranged from 450 to 900 mg/day. After normalization by weight and daily dose, the normalized OXC concentration was 0.86 (0.68-1.09) mg/ml/(mg/kg). After 1 year of OXC treatment, up to two thirds of patients received good efficacy.
Results
Study characteristics
Relationships between the genetic polymorphisms and OXC concentrations
Each genotype frequency was consistent with Hardy-Weinberg equilibrium, and was similar to those of patients with epilepsy and healthy controls in the previous studies with Han Chinese sample [13, 21, 22] (Table 2) . Of the four candidate SNPs, ABCB1 rs1045642 showed a significant association with the normalized OXC concentration (P = 0.047). Compared with CT and TT genotypes, CC genotype of ABCB1 rs1045642 was associated with a higher OXC concentration (CC vs. CT + TT [median with P 25 -P 75 ]: 1.00[0.73-1.15] vs. 0.83[0.59-1.08] (mg/ml/ml)/(mg/kg), P = 0.020). Multivariate regression analysis was performed to evaluate the combined effects of ABCB1 rs1045642 and non-genetic factors on the OXC concentration after adjustment for cofactors such as gender, disease duration (>1 year), family history and seizure type, the association remained significant (P = 0.040). No significant intergroup differences of OXC daily dose, gender distribution, age, height and weight were found.
As for ABCC2 rs2273697, UGT2B7 rs7439366 and HNF4a rs2071197 SNPs, we failed to detect any significant associations between genotypes and OXC daily doses, normalized plasma concentrations.
Relationships between the genetic polymorphisms and therapeutic efficacy
To investigate the effects of genetic polymorphisms on OXC responsiveness, patients were divided into different groups according to each SNP. ABCB1 rs1045642 and UGT2B7 rs7439366 exhibited a significant correlation with treatment response. As shown in Table 3 , there were more OXC-responsive patients carrying the ABCB1 rs1045642 CC than those carrying CT (P = 0.025) and TT (P = 0.022). Compared with those carrying T allele, more patients carrying C allele showed good efficacy (P = 0.009). Besides, the polymorphism of UGT2B7 rs7439366 exhibited a correlation with therapeutic efficacy (C vs. T P = 0.036). The genotype and allele frequencies of ABCC2 and HNF4a did not differ significantly between good efficacy and poor efficacy group (Table 3) .
Multivariate logistic analysis was also performed to evaluate the combined effects of SNPs and non-genetic factors on the OXC responsiveness after adjustment for the above cofactors. Among the analyzed genes, only ABCB1 rs1045642 had a significant effect on the OXC responsiveness (CC vs. CT + TT: Odds ratios (ORs) = 3.08, 95% confidence interval (95% CI) 1.25-7.56, p = 0.014).
Discussion
This study demonstrated that ABCB1 rs1045642 polymorphism was significantly associated with normalized OXC concentration and therapeutic outcome in Han Chinese patients with epilepsy. The polymorphism of UGT2B7 rs7439366 exhibited a correlation with OXC responsiveness, but not OXC concentration. Besides, we failed to observe any correlations between ABCC2, HNF4a polymorphisms and OXC concentrations and treatment outcome in the cohort.
The ABCB1 gene encodes P-gp, which is highly polymorphic. C3435T in exon 26 (rs1045642) is the most extensively studied ABCB1 SNP [23] . A number of studies have reported the correlations among ABCB1 rs1045642 polymorphism and AED pharmacokinetics [8, 24, 25] , but few studies were focused on OXC. In the present study, we showed that patients with epilepsy with the CC genotype of ABCB1 rs1045642 had a higher OXC concentration in comparison with CT and TT genotypes, suggesting patients with homozygous wild-type carriers required lower OXC maintenance dose to achieve the referenced effective plasma level. This was consistent with a previous study [6] , which demonstrated that ABCB1 rs1045642 CC was associated with increased plasma CBZ levels. However, Wang et al's study has only indicated that ABCB1 rs2032582 and rs2032582-rs10234411-rs1045642 TAG haplotype were significantly associated with MHD and MHD + OXC plasma concentration in the group on OXC + Valproic acid (VPA) polytherapy, but no associations were observed between ABCB1 rs1045642 and plasma OXC concentration in patients with epilepsy receiving OXC monotherapy [11] , which was inconsistent with our study. One explanation may be the limited sample of Wang et al's study that enrolled 40 patients with epilepsy. A previous metaanalysis has concluded that ABCB1 rs1045642 polymorphism was not associated with drug resistance in patients with epilepsy [26] , however recent studies showed the positive association, especially in Caucasians [27, 28] . All the studies focused on various AEDs, to date, our study was the first analysis to evaluate the association between ABCB1 polymorphism and OXC therapeutic efficacy. According to literature data, ABCB1 rs1045642 does not result in an amino acid change but in altered protein conformations, which may consequently affects the function of P-gp [29] . In the present study, patients carrying the homozygous CC genotype of ABCB1 rs1045642 was more likely to be OXC-responsive. It seemed reasonable as CC genotype reduced the efflux activity of P-gp, increased the OXC concentration, and then resulted in good efficacy. However, the underlying molecular mechanism remians unclear.
UGT enzymes are a superfamily of key proteins that catalyze the glucuronidation of a wide range of AEDs, including Lamotrigine (LTG), CBZ and OXC [15, 30, 31] . A recent study have revealed that carriers of the UGT1A9 variant allele I399 C > T had significantly lower MHD plasma concentrations and poorer seizure control than Rest of data were presented as M (median) with P 25 -P 75 (Percentile: 25%-75%).
noncarriers [16] . As for UGT2B7 rs7439366, the polymorphism causes a histidine-to-tyrosine substitution at position 268 of the protein, whose allele frequency in the Chinese population is 32.8% [32, 33] . Our study demonstrated that patients carrying T allele of UGT2B7 rs7439366 was more likely to be effective in comparison with those carrying C allele, which was in agreement with Ma et al's study [13] , as homozygous wild-type carriers of UGT2B7 rs7439366 variant allele required significantly lower OXC maintenance doses than homozygous and heterozygous carriers. However, neither studies showed the correlation between the SNP and adjusted OXC concentration. It may be explained by the different parameters, because the OXC maintenance dose in Ma et al's study was defined as a dose that had not been changed for at least 1 year in association with good compliance and seizure control. On the whole, UGT2B7 may be useful for the personalization of OXC therapy in patients with epilepsy. The present study failed to observe a significant correlation among ABCC rs2273697 and adjusted OXC concentration and therapeutic efficacy, which was inconsistent with previous studies [12, 13] . Considering the different parameters and ethnic groups, further studies are still needed. Similarly, HNF4a rs2071197 was not associated with OXC concentration and treatment outcome, suggesting HNF4a genetic variants might not take part in the metabolism and transport of OXC among patients with epilepsy using OXC monotherapy.
The study has some limitations. First, the present study did not explore the correlation between the candidate SNPs and MHD concentrations, as the MHD was not routinely measured in clinical practice. Second, there were multiple factors that may affect OXC pharmacokinetics and treatment outcome, therefore the possibility of confounders remains, such as other SNPs. At last, the sample size was not large enough.
In our routine therapeutic drug monitoring, we monitored more and more OXC plasma concentrations of patients with epilepsy and observed that the variability among individuals was large. As the first study to confirm the positive effect of ABCB1 rs1045642 genetic polymorphism on OXC metabolism, our findings reveal the importance of evaluating the role of genetic variation on interindividual variation of OXC plasma concentration, especially when patients are in good compliance. This study may facilitate the personalized OXC therapy in patients with epilepsy. Future studies can replicate our research with a larger cohort and explore the regulatory mechanism of ABCB1 genetic variations. Data in daily dose and OXC concentration were presented as M (median) with P 25 -P 75 (Percentile: 25%-75%). *P < 0.05 was statistically significant. 
